Abstract：
BACKGROUND: The concurrent use of bleomycin and granulocyte colony-stimulating factors (G-CSFs) has historically been debated as a risk factor for bleomycin-induced pulmonary toxicity in patients with both testicular cancer and Hodgkin\'s lymphoma. The purpose of this study is to evaluate the incidence of pulmonary toxicity in patients with testicular cancer who were treated with bleomycin and pegfilgrastim concurrently.
METHODS: This is a retrospective study that includes male patients over the age of 18 years old diagnosed with testicular cancer who received bleomycin-containing chemotherapy regimens with and without the use of G-CSF agents.
RESULTS: There were a total of 33 patients identified as receiving bleomycin, with 30 of those patients having received concurrent G-CSF therapy. Of the patients who received G-CSF therapy, 11 patients (36.6%) experienced pulmonary toxicity leading to discontinuation of bleomycin or changes in chemotherapy regimens altogether.
CONCLUSIONS: There were no major differences in patient demographics or risk factors between those who received G-CSF and developed pulmonary toxicity and those who received G-CSF but did not develop pulmonary toxicity. Further studies are needed in order to fully assess the risk of pulmonary toxicity with this chemotherapy regimen.
METHODS: This is a retrospective study that includes male patients over the age of 18 years old diagnosed with testicular cancer who received bleomycin-containing chemotherapy regimens with and without the use of G-CSF agents.
RESULTS: There were a total of 33 patients identified as receiving bleomycin, with 30 of those patients having received concurrent G-CSF therapy. Of the patients who received G-CSF therapy, 11 patients (36.6%) experienced pulmonary toxicity leading to discontinuation of bleomycin or changes in chemotherapy regimens altogether.
CONCLUSIONS: There were no major differences in patient demographics or risk factors between those who received G-CSF and developed pulmonary toxicity and those who received G-CSF but did not develop pulmonary toxicity. Further studies are needed in order to fully assess the risk of pulmonary toxicity with this chemotherapy regimen.
摘要：
背景：博来霉素和粒细胞集落刺激因子（G-CSF）的同时使用历来被认为是睾丸癌和霍奇金淋巴瘤患者博来霉素诱导的肺毒性的危险因素。这项研究的目的是评估同时接受博来霉素和pegfilgrastim治疗的睾丸癌患者的肺毒性发生率。
方法：这是一项回顾性研究，包括18岁以上被诊断患有睾丸癌的男性患者，这些患者接受含有博来霉素的化疗方案，有或没有使用G-CSF药物。
结果：共有33名患者被确定为接受博来霉素治疗，其中30例患者同时接受了G-CSF治疗。在接受G-CSF治疗的患者中，11例患者（36.6％）出现肺毒性，导致博来霉素停药或完全改变化疗方案。
结论：接受G-CSF并出现肺毒性的患者和接受G-CSF但未出现肺毒性的患者在患者的人口统计学或危险因素方面没有重大差异。需要进一步的研究来全面评估这种化疗方案的肺毒性风险。
方法：这是一项回顾性研究，包括18岁以上被诊断患有睾丸癌的男性患者，这些患者接受含有博来霉素的化疗方案，有或没有使用G-CSF药物。
结果：共有33名患者被确定为接受博来霉素治疗，其中30例患者同时接受了G-CSF治疗。在接受G-CSF治疗的患者中，11例患者（36.6％）出现肺毒性，导致博来霉素停药或完全改变化疗方案。
结论：接受G-CSF并出现肺毒性的患者和接受G-CSF但未出现肺毒性的患者在患者的人口统计学或危险因素方面没有重大差异。需要进一步的研究来全面评估这种化疗方案的肺毒性风险。
